Price Paul W, McKinney Elizabeth C, Wang Youliang, Sasser Loren E, Kandasamy Muthugapatti K, Matsuuchi Linda, Milcarek Christine, Deal Roger B, Culver Deborah G, Meagher Richard B
Abeome Corporation, Athens, GA 30605, USA.
J Immunol Methods. 2009 Mar 31;343(1):28-41. doi: 10.1016/j.jim.2009.01.005. Epub 2009 Jan 31.
Monoclonal antibodies (mAbs) have proven to be effective biological reagents in the form of therapeutic drugs and diagnostics for many pathologies, as well as valuable research tools. Existing methods for isolating mAb-producing hybridomas are tedious and time consuming. Herein we describe a novel system in which mAb-secreting hybridoma cells were induced to co-express significant amounts of the membrane form of the secreted immunoglobulin (Ig) on their surfaces and are efficiently recovered by fluorescent activated cell sorting (FACS). Fusion of a novel myeloma parent, SP2ab, expressing transgenic Igalpha and Igbeta of the B-cell receptor complex (BCR) with spleen cells resulted in hybridomas demonstrating order of magnitude increases in BCR surface expression. Surface Ig levels correlated with transgenic Igalpha expression, and these cells also secreted normal levels of mAb. Hundreds of hybridoma lines producing mAbs specific for a variety of antigens were rapidly isolated as single cell-derived clones after FACS. Significant improvements using the Direct Selection of Hybridomas (DiSH) by FACS include reduced time and labor, improved capability of isolating positive hybridomas, and the ease of manipulating cloned cell lines relative to previously existing approaches that require Limiting Dilution Subcloning (LDS).
单克隆抗体(mAbs)已被证明是治疗多种疾病的有效生物试剂,可作为治疗药物和诊断试剂,也是有价值的研究工具。现有的分离产生单克隆抗体的杂交瘤的方法既繁琐又耗时。在此,我们描述了一种新系统,在该系统中,分泌单克隆抗体的杂交瘤细胞被诱导在其表面共表达大量分泌型免疫球蛋白(Ig)的膜形式,并通过荧光激活细胞分选(FACS)有效地回收。一种表达B细胞受体复合物(BCR)转基因Igalpha和Igbeta的新型骨髓瘤亲本SP2ab与脾细胞融合,产生的杂交瘤在BCR表面表达上有数量级的增加。表面Ig水平与转基因Igalpha表达相关,并且这些细胞也分泌正常水平的单克隆抗体。通过FACS直接选择杂交瘤(DiSH)后,数百个产生针对多种抗原的单克隆抗体的杂交瘤细胞系作为单细胞衍生克隆被快速分离出来。与需要有限稀释亚克隆(LDS)的现有方法相比,使用FACS直接选择杂交瘤(DiSH)的显著改进包括减少时间和劳动力、提高分离阳性杂交瘤的能力以及易于操作克隆细胞系。